InMed Pharmaceuticals (IMLFF) Lead Product Candidate Targeting Rare, Incurable Skin Disease

From The QualityStocks Daily Blog for Micro-cap and Small-Cap Companies
March 16, 2017 - 1:14pm
With a prevalence of 20 per million newborns in the United States, and an estimated 500,000 patients worldwide, epidermolysis bullosa is a group of rare inherited skin diseases that range in severity from mild to lethal and have no currently approved or known cure or treatment. The condition was brought to the public attention in […]

Continue reading this article »